PMID- 36362221
OWN - NLM
STAT- MEDLINE
DCOM- 20221114
LR  - 20221207
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 21
DP  - 2022 Nov 3
TI  - Lactobacillus sakei MJM60958 as a Potential Probiotic Alleviated Non-Alcoholic 
      Fatty Liver Disease in Mice Fed a High-Fat Diet by Modulating Lipid Metabolism, 
      Inflammation, and Gut Microbiota.
LID - 10.3390/ijms232113436 [doi]
LID - 13436
AB  - Non-alcoholic fatty liver disease (NAFLD) is a common liver disease with a 
      rapidly increasing number of cases worldwide. This study aimed to evaluate the 
      effects of Lactobacillus sakei MJM60958 (MJM60958) on NAFLD in vitro and in vivo. 
      In in vitro tests, MJM60958 significantly inhibited lipid accumulation by 46.79% 
      in HepG2 cells stimulated with oleic acid and cholesterol (OA-C). Moreover, 
      MJM60958 showed safe and probiotic characteristics in vitro. In the animal study, 
      MJM60958 administration in a high-fat diet-induced NAFLD mouse model 
      significantly reduced body weight and liver weight, and controlled aspartate 
      aminotransferase (ALT), aspartate transaminase (AST), triglyceride (TG), urea 
      nitrogen (BUN), and uric acid (UA) levels in the blood, which are features of 
      NAFLD. Further, treatment with MJM60958 also reduced steatosis scores in liver 
      tissues, serum leptin and interleukin, and increased serum adiponectin content. 
      Moreover, administration of MJM60958 resulted in a significantly decreased 
      expression of some genes and proteins which are related to lipid accumulation, 
      such as fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), and sterol 
      regulatory element-binding protein 1 (SREBP-1), and also upregulated genes and 
      protein expression of lipid oxidation such as peroxisome proliferator-activated 
      receptor alpha (PPARalpha) and carnitine palmitoyltransferase 1a (CPT1A). 
      Administration of MJM60958 increased the relative abundance of specific microbial 
      taxa such as Verrucomicrobia, which are abundant in non-NAFLD mice, and reduced 
      Firmicutes, which are a major group in NAFLD mice. MJM60958 affected the 
      modulation of gut microbiota and altered the strain profile of short-chain fatty 
      acids (SCFAs) production in the cecum by reduced lactic acid and enhanced acetic 
      acid production. Overall, MJM60958 showed potential as a probiotic that can 
      prevent and treat NAFLD.
FAU - Nguyen, Huong Thi
AU  - Nguyen HT
AUID- ORCID: 0000-0002-9829-0290
AD  - Interdisciplinary Program of Biomodulation, Myongji University, Yongin 17058, 
      Korea.
FAU - Gu, Mingkun
AU  - Gu M
AUID- ORCID: 0000-0003-1894-8409
AD  - Interdisciplinary Program of Biomodulation, Myongji University, Yongin 17058, 
      Korea.
FAU - Werlinger, Pia
AU  - Werlinger P
AD  - Interdisciplinary Program of Biomodulation, Myongji University, Yongin 17058, 
      Korea.
FAU - Cho, Joo-Hyung
AU  - Cho JH
AD  - Myongji Bioefficacy Research Center, Myongji University, Yongin 17058, Korea.
FAU - Cheng, Jinhua
AU  - Cheng J
AD  - Interdisciplinary Program of Biomodulation, Myongji University, Yongin 17058, 
      Korea.
AD  - Myongji Bioefficacy Research Center, Myongji University, Yongin 17058, Korea.
FAU - Suh, Joo-Won
AU  - Suh JW
AD  - Interdisciplinary Program of Biomodulation, Myongji University, Yongin 17058, 
      Korea.
AD  - Myongji Bioefficacy Research Center, Myongji University, Yongin 17058, Korea.
LA  - eng
GR  - PJ01640201/Cooperative Research Program for Agriculture Science and Technology 
      Development, Rural Development Administration/
PT  - Journal Article
DEP - 20221103
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Triglycerides)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Non-alcoholic Fatty Liver Disease/drug therapy/etiology
MH  - Diet, High-Fat/adverse effects
MH  - Lipid Metabolism
MH  - *Latilactobacillus sakei
MH  - *Gastrointestinal Microbiome
MH  - Liver/metabolism
MH  - Inflammation/metabolism
MH  - Triglycerides/metabolism
MH  - *Probiotics/pharmacology/therapeutic use
MH  - Mice, Inbred C57BL
PMC - PMC9658623
OTO - NOTNLM
OT  - Lactobacillus sakei MJM60958
OT  - NAFLD
OT  - SCFAs
OT  - microbiota
OT  - probiotics
COIS- The authors declare no conflict of interest.
EDAT- 2022/11/12 06:00
MHDA- 2022/11/15 06:00
PMCR- 2022/11/03
CRDT- 2022/11/11 01:28
PHST- 2022/09/07 00:00 [received]
PHST- 2022/10/28 00:00 [revised]
PHST- 2022/10/31 00:00 [accepted]
PHST- 2022/11/11 01:28 [entrez]
PHST- 2022/11/12 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/11/03 00:00 [pmc-release]
AID - ijms232113436 [pii]
AID - ijms-23-13436 [pii]
AID - 10.3390/ijms232113436 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Nov 3;23(21):13436. doi: 10.3390/ijms232113436.